Minerva Neurosciences Appoints Carlos Martin as Chief Commercial Officer to Enhance Leadership

Neurvati Neurosciences Strengthens Leadership with Appointment of Carlos Martin as Chief Commercial Officer

Neurvati Neurosciences, a prominent player in the biopharmaceutical sector, announces the appointment of Carlos Martin as its Chief Commercial Officer (CCO), effective November 13, 2025. With over two decades of experience in global biopharmaceutical markets, Martin brings a wealth of expertise in building commercial organizations and launching innovative therapies across various fields, including gene therapy, oncology, and rare diseases. This strategic hire is aimed at fortifying Neurvati’s commercial strategies, thereby enhancing the market trajectory of its neuroscience therapies.

Before joining Neurvati, Martin held the position of CCO at Rocket Pharmaceuticals, where he was instrumental in transitioning the company from a clinical-stage biotech to a commercially viable entity. His accomplishments there included crafting comprehensive strategies for market entry in the U.S., EU, and Japan, while also securing essential pre-launch agreements with payers. His tenure at Novartis Pharmaceuticals further underscores his capabilities; he managed a $1 billion oncology portfolio and played a pivotal role in establishing the radiopharmaceutical commercial business in the U.S. These experiences position Martin as a key asset for Neurvati, where he will focus on aligning commercial strategy with the company’s scientific advancements.

Bruce Leuchter, M.D., President & CEO of Neurvati, highlights that Martin's extensive experience in innovative therapeutic areas will be critical in translating the company's scientific advancements into market-ready solutions. The establishment of the CCO role underscores Neurvati's commitment to integrating commercial strategies early in the development process. This integration aims to enhance the value proposition of their neuroscience therapies for various stakeholders, including patients, healthcare providers, payors, and health systems. Martin expresses his eagerness to build a robust global commercial framework that ensures Neurvati’s therapies reach those who need them most, supporting the company's mission to deliver clinically validated programs with significant patient impact and high market value.

In addition to this appointment, Neurvati continues to emphasize its dedication to advancing neuroscience therapies that can offer transformative benefits to patients. By appointing a leader with Martin's track record, the company aims to solidify its position in a competitive market and ensure that its innovative therapies are successfully launched and adopted.

Neurvati's forward-looking approach, reflected in the strategic appointment of Martin, positions the company well for future growth and success in the biopharmaceutical landscape. The integration of experienced leadership in commercial operations is a crucial step in realizing the potential of its neuroscience innovations.